Cited by 209RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics

Open access
Xu, Long, Anchordoquy, Thomas·2011·Journal of Pharmaceutical Sciences

Abstract

The ability to deliver nucleic acids (e.g., plasmid DNA, antisense oligonucleotides, siRNA) offers the potential to develop potent vaccines and novel therapeutics. However, nucleic acid-based therapeutics are still in their early stages as a new category of biologics. The efficacy of nucleic acids requires that these molecules be delivered to the interior of the target cell, which greatly complicates delivery strategies and compromises efficiency. Due to the safety concerns of viral vectors, synthetic vectors such as liposomes and polymers are preferred for the delivery of nucleic acid-based therapeutics. Yet, delivery efficiencies of synthetic vectors in the clinic are still too low to obtain therapeutic levels of gene expression. In this review, we focus on some key issues in the field of nucleic acid delivery such as PEGylation, encapsulation and targeted delivery and provide some perspectives for consideration in the development of improved synthetic vectors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jps.22243

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cationic non-viral vectors used to condense negatively charged CRISPR RNPs and plasmids are prone to interact with plasma proteins and physiological salt, resulting in recognition and clearance by RES.

    “On the other hand, cationic non-viral vectors used to condense negatively charged CRISPR RNPs and plasmids are prone to interact with plasma proteins and the physiological salt in physiological conditions, resulting in the recognition and clearance by the reticuloendothelial system (RES) [141–143].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 155 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [9]2009 Gene therapy clinical trials world wide Journal of Gene Medicine http://www.wiley.co.uk/genetherapy/clinical/

Cited by

Sorted by citations

Authors
Xu, L., & Anchordoquy, T.
Affiliations
University of Colorado Denver (US)
Corresponding author
Anchordoquy, Thomas
Venue
Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2011-01
Volume
100
Issue
1
Pages
38-52
ISSN
0022-3549 (ISSN-L)
OpenAlex
W2090160156
Cited by
209
References
155
Citations by year
2026: 8 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 7 · 2021: 6 · 2020: 9 · 2019: 9 · 2018: 9 · 2017: 14 · 2016: 13 · 2015: 14 · 2014: 15 · 2013: 28 · 2012: 28
Type
journal article
Language
en
Open access
Locations
  • Journal of Pharmaceutical Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Biomedical Imaging and Bioengineering (R01EB005476)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
nucleic acid delivery, nucleic acid therapeutics, antisense oligonucleotides, siRNA, plasmid DNA, liposomes, polymeric vectors, PEGylation, encapsulation, targeted delivery, synthetic vectors, gene therapy, drug delivery
MeSH terms
Animals, Biological Therapy, Chemistry, Pharmaceutical, Humans, Nucleic Acids, Oligonucleotides, Plasmids, Oligonucleotides, Antisense, Drug Delivery Systems, Vaccines, DNA, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review